Roche's fenebrutinib showed almost total reduction in disease activity and disability advancement for as long as 48 weeks in patients with relapsing multiple sclerosis.

Invivyd starts initial dosing in Phase 1 trial of VYD2311, a new monoclonal antibody for COVID-19, expanding on PEMGARDA™'s success.

Biogen Reports Encouraging Topline Results from Study on Higher Dose of Nusinersen, Demonstrating Notable Success in SMA Treatment.

OncoC4 Starts Phase 1 Trial Dosing First Patient with the New SIGLEC10 Checkpoint Inhibitor ONC-841 for Solid Tumors.

Allyx Therapeutics has begun a new clinical trial for its key drug, ALX-001, administering it to the first patient to assess safety, pharmacokinetics, and potential therapeutic effects in Parkinson’s disease.

Merck and EyeBio Announce Start of Phase 2b/3 Clinical Study for Restoret™ to Treat Diabetic Macular Edema.

BlueRock Therapeutics has obtained FDA approval for their IND application for OpCT-001, a cell therapy derived from iPSCs, targeting primary photoreceptor diseases.

Vasa Therapeutics Begins Phase 1 Human Trial of VS-041 for Treating Heart Failure with Preserved Ejection Fraction.

GC Biopharma revealed that its joint effort with Hanmi Pharmaceutical on the Fabry treatment 'LA-GLA' (GC1134A/HM15421) has been granted IND approval by the U.S. FDA to initiate a Phase 1/2 clinical study.

REGENXBIO Inc. revealed encouraging findings from the Phase I/II/III CAMPSIITE® study of RGX-121, aimed at treating Mucopolysaccharidosis Type II (MPS II).

Evommune has announced the initiation of a Phase 2 trial for EVO756, with the first patient now enrolled.

The EC has authorized the use of Merck's KEYTRUDA® (pembrolizumab) in combination with Padcev® (enfortumab vedotin-ejfv) as an initial therapy for adults with inoperable or metastatic urothelial cancer.